Answers are grounded in this paper and cite their sources.
Colorectal cancer (CRC) remains a leading cause of cancer-related mortality worldwide, with its heterogeneous molecular profiles complicating prognosis prediction. Multi-omics profiling of clinical CRC specimens is particularly valuable for uncovering prognostic variables; however, such integrated studies remain scarce. Here, we applied the Multi-Omics Factor Analysis v2 framework to multi-omics data (mutations, miRNA, RNA, proteomics, phospho-proteomics) from the CPTAC-2 cohort and constructed a comprehensive CRC model. This approach identified a survival-associated latent variable, which we term the CRC Prognostic Latent Factor (CPLF). The prognostic relevance of CPLF was then rigorously validated across three independent multi-omics cohorts, encompassing 579 patients with CRC. CPLF primarily reflects extracellular matrix deposition in the tumour microenvironment, with Tensin 1 (TNS1) and Fermitin family homologue 2 (FERMT2) as the highest-weighted features. Single-cell and spatial transcriptomic analyses, supplemented by immunohistochemistry, localized CPLF-associated gene expression predominantly to myofibroblasts. Functionally, knockdown of Tensin 1 or FERMT2 in fibroblasts attenuated tumour growth in vivo. Consistently, these top-weighted components of CPLF upregulated fibronectin 1 (FN1) expression in myofibroblasts, thereby activating integrin signaling in cancer cells and enhancing tumour progression. Altogether, our findings unveil CPLF as a data-inherent multi-omics prognostic factor and establish the CPLF/FN1/integrin axis as a key pathway mediating myofibroblast-cancer cell crosstalk in CRC progression.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: